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Fragile X mental retardation protein controls
synaptic vesicle exocytosis by modulating
N-type calcium channel density
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Fragile X syndrome (FXS), the most common heritable form of mental retardation, is
characterized by synaptic dysfunction. Synaptic transmission depends critically on
presynaptic calcium entry via voltage-gated calcium (CaV) channels. Here we show that the
functional expression of neuronal N-type CaV channels (CaV2.2) is regulated by fragile X
mental retardation protein (FMRP). We ﬁnd that FMRP knockdown in dorsal root ganglion
neurons increases CaV channel density in somata and in presynaptic terminals. We then show
that FMRP controls CaV2.2 surface expression by targeting the channels to the proteasome
for degradation. The interaction between FMRP and CaV2.2 occurs between the carboxy-
terminal domain of FMRP and domains of CaV2.2 known to interact with the neurotransmitter
release machinery. Finally, we show that FMRP controls synaptic exocytosis via CaV2.2
channels. Our data indicate that FMRP is a potent regulator of presynaptic activity, and its
loss is likely to contribute to synaptic dysfunction in FXS.
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F
ragile X syndrome (FXS) is the most common inherited
form of intellectual disability, often associated with
autism1,2. FXS is caused, in the vast majority of cases, by a
trinucleotide repeat expansion in the 50-UTR of the fragile X
mental retardation 1 (FMR1) gene, leading to its hyper-
methylation and transcriptional silencing. The FMR1 gene
encodes fragile X mental retardation protein (FMRP), an RNA-
binding protein that participates in the trafﬁcking of messenger
RNA (mRNAs) to distal sites in neurons, especially dendrites of
central neurons3. FMRP suppresses translation of mRNAs to
which it binds, but also regulates the activity-dependent
translation of these mRNAs, particularly in response to group I
metabotropic glutamate receptor activation4,5. These ﬁndings
show that dendritic FMRP is critical for postsynaptic activity of
neurons6.
A growing body of evidence points to an additional role for
FMRP in presynaptic function7–9. For example, a recent study
showed that Fmr1 knockout mice have abnormal presynaptic
short-term plasticity in hippocampal neurons10. This opened the
possibility that there is an effect of FMRP on presynaptic voltage-
gated calcium (CaV) channels.
The CaV family plays a major role in the physiology of
excitable cells11. Three subfamilies have been identiﬁed: CaV1–3.
The CaV1 (L-type) and CaV2 (N-, P/Q- and R-type) channels are
thought to be heteromultimers composed of the pore-forming a1-
subunit, associated with auxiliary CaVb- and CaVa2d-subunits11.
N-type calcium channels (CaV2.2) are present in both the central
and peripheral nervous systems, and they have a major
presynaptic role in regulation of transmitter release12,13. The
intracellular loop between domains II and III and the C-terminal
tail of CaV2 a1-subunits interact with presynaptic proteins that
modulate calcium currents and the targeting of these channels to
synaptic terminals14. Since there are precedents for interaction of
FMRP with ion channels, speciﬁcally the sodium-activated Kþ
channel (Slack-B)15 and the calcium-activated potassium channel
(BK)16, we examined whether FMRP could directly affect calcium
channel function.
Here we show that CaV channel density in dorsal root ganglion
(DRG) neurons is increased at the cell surface of the soma and the
presynaptic terminals when FMRP is knocked down with small
hairpin RNA (shRNA). We then show that FMRP reduces
CaV2.2-generated currents by decreasing the expression of the
channel at the plasma membrane, and we provide evidence that
this mechanism involves proteasomal degradation. We also show
that the interaction between FMRP and CaV2.2 is direct, since we
ﬁnd that the C-terminal domain of FMRP binds to the CaV2.2
II–III linker and C-terminal domains. Finally, using a pharmaco-
logical approach, we show that FMRP modulates synaptic vesicle
release via CaV2.2 channels. Our data demonstrate an unexpected
effect of FMRP on CaV2.2 channel functional expression, and
indicate a new role for FMRP in presynaptic function.
Results
FMRP regulates CaV2.2 expression in DRG neurons. To
determine the impact of FMRP on CaV currents in DRG neurons,
we silenced FMRP expression using RNA interference. Knock-
down of FMRP was validated in tsA-201 cells expressing green
ﬂuorescent protein (GFP)-FMRP and in cultured DRG neurons
(Supplementary Fig. 1). We then examined the effect of FMRP
knockdown on calcium currents in DRG neurons 4 days after
shRNA transfection (Fig. 1a,b). We found that, in DRG neurons
in which FMRP was knocked down, the peak CaV current density
was increased by 103% (Fig. 1b). Previous work found that
N-type calcium currents account for the major component of
calcium current in DRG neurons17. We then examined the
impact of FMRP knockdown on CaV2.2 surface expression. To do
this, we transfected DRG neurons with a CaV2.2 channel
construct tagged with an exofacial HA epitope and either
control shRNA or FMRP shRNA (Fig. 1c). We found that HA-
CaV2.2 immunoreactivity at the cell surface was increased by 45%
in neurons in which FMRP was knocked down (Fig. 1c,d).
We then took advantage of the fact that DRG neurons form
functional synapses, when co-cultured with dorsal horn (DH)
neurons18, to investigate the impact of FMRP on CaV2.2
expression at presynaptic terminals. P2 DRG neurons were co-
microinjected with HA-CaV2.2 and the presynaptic protein
VAMP-1, tagged with mCherry, together with either control
shRNA or FMRP shRNA (Fig. 1e,f). We found that HA-CaV2.2
immunoreactivity in VAMP-mCherry-positive boutons in non-
permeabilized processes was increased by 48% in neurons in
which FMRP was knocked down (Fig. 1g). Finally, we assessed
CaV2.2 expression in brain synaptosomes from Fmr1 knockout
mice (Fig. 1h). We found that the level of CaV2.2 protein in
synaptosomes was increased by 43% in Fmr1 knockout mice
compared with wild-type mice. Together, our data reveal that
FMRP controls the presynaptic expression of CaV2.2 in DRG
neurons.
FMRP controls CaV2.2 current density. To characterize the
functional effect of FMRP on N-type calcium channels, we
recorded Ba2þ currents (IBa) from tsA-201 cells co-transfected
Figure 1 | FMRP knockdown increases CaV currents and enhances surface expression of CaV2.2 channels in soma and presynaptic terminals
of DRG neurons. (a) Typical calcium channel current traces recorded from DRG neurons transfected with Ctrl shRNA (top) or FMRP shRNA (bottom),
elicited by 50ms step depolarizations between  50 and þ 60mV from a holding potential (HP) of 80mV. The charge carrier was 10mM Ba2þ .
(b) Current–voltage relationship for calcium channel current (IBa) recorded from DRG neurons transfected with Ctrl shRNA (ﬁlled squares, n¼ 16) or FMRP
shRNA (open squares, n¼ 14). Peak currents were normalized to the cell capacitance. For þ 20mV, IBa was  66.7±10.3 pA/pF in Ctrl shRNA
(n¼ 16) and  134.3±15.8 pA/pF in FMRP shRNA (n¼ 14, P¼0.001). The mean data are ﬁtted with a modiﬁed Boltzmann function (see Methods) with
V50,act of þ 7.9±1.6 and þ 5.8±0.8mV, respectively, and Gmax of 1.9±0.2 and 3.1±0.2 nS/pF, respectively. Means±s.e.m., ***Po0.001; one-way
ANOVA. (c) Representative confocal images of HA staining from non-permeabilized DRG neurons expressing HA-CaV2.2/CaVb1b/CaVa2d-1 with Ctrl
shRNA (left) or FMRP shRNA (right). Scale bar, 20mm. (d) Bar chart showing normalized cell surface expression of HA-CaV2.2 in DRG neurons expressing
Ctrl shRNA (ﬁlled bar, 100±10%, n¼ 51 cells) or FMRP shRNA (open bar, 145±12%, n¼ 62 cells, P¼0.006). Means±s.e.m., **Po0.01; one-way
ANOVA. (e,f) Representative confocal images of non-permeabilized DRG neuron processes expressing HA-CaV2.2/CaVb1b/CaVa2d-1/VAMP-mCherry
with Ctrl shRNA (e) or FMRP shRNA (f). Top panels show HA-CaV2.2 immunostaining, middle panels show VAMP-mCherry and bottom panels show
merged HA-CaV2.2 immunostaining (green) with presynaptic VAMP-mCherry (red). Bouton regions are indicated by the white circles. Scale bars, 10mm.
(g) Bar chart showing normalized cell surface expression of HA-CaV2.2 in boutons of DRG neurons expressing Ctrl shRNA (ﬁlled bar, 100±10%, n¼ 73)
and FMRP shRNA (open bar, 148±15%, n¼ 50, P¼0.006). Means±s.e.m., **Po0.01; one-way ANOVA. (h) Immunoblotting for CaV2.2 in brain
synaptosomes from Fmr1 knockout (KO) and wild-type (WT) mice. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) provides a loading control for
CaV2.2 quantiﬁcation. CaV2.2 expression in brain synaptosomes from Fmr1 knockout mice is increased by 43% (average of two independent experiments,
38 and 48%). Full-size blots can be found in Supplementary Fig. 8.
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with CaV2.2 (together with auxiliary subunits CaVb1b and
CaVa2d-1) and GFP-FMRP. We found that FMRP signiﬁcantly
reduced peak CaV2.2 IBa current density at þ 10mV by 80%
(Fig. 2a,b).
A reduction of current density can result from a loss of
functional channels at the plasma membrane and/or a modiﬁca-
tion of the biophysical properties of the channels. No difference
in the voltage dependence of activation for the current density–
voltage relationships was observed when FMRP was co-expressed
with CaV2.2 (Fig. 2b) and this was conﬁrmed by tail current
analysis (Fig. 2c,d). However, we noted a consistent depolarizing
shift of the CaV2.2 steady-state inactivation curve when FMRP
was co-expressed (Fig. 2e,f). This latter modiﬁcation is not
responsible for the reduction of current density but nevertheless it
suggests that FMRP may be interacting with intracellular domains
of CaV2.2 involved in voltage-dependent inactivation. We also
examined the kinetics of decay of the current, but observed no
modiﬁcation of the time constant of inactivation (Fig. 2g).
Importantly, the reduction in current density was still evident
using the physiological charge carrier, Ca2þ ; FMRP reduced peak
CaV2.2 ICa density at 0mV by 55% (Fig. 2h).
Since FMRP has been shown to modulate the gating of Slack-B
channels15, we therefore assessed the impact of FMRP on CaV2.2
channel activity. Using ﬂuctuation analysis, we found that FMRP
Ctrl shRNA
a b
c d
e f
g h
+60 mV
–50 mV
–60 0
Ctrl shRNA
FMRP shRNA
100
pA/pF
***
200
100
0
FMRP shRNA
HA-Cav2.2
VAMP-mCherry
Merge
Ctrl shRNA
Ca
v2
.2
 s
ur
fa
ce
 e
xp
re
ss
io
n
in
 th
e 
so
m
a 
(re
lat
ive
 H
A
im
m
un
of
lu
or
es
ce
nc
e)
**
60
2 nA
mV
20 ms
–80 mV
FMRP shRNA
Ctrl shRNA FMRP shRNA
HA-Cav2.2
VAMP-mCherry
Merge
**
200
100
0Ca
v2
.2
 s
ur
fa
ce
 e
xp
re
ss
io
n
in
 b
ou
to
ns
 (r
ela
tiv
e H
A
im
m
un
of
lu
or
es
ce
nc
e)
38
225
kDa
KO WT
Cav2.2
GAPDH
Brain synaptosomes
Ctrl
shRNA
FMRP
shRNA
Ctrl
shRNA
FMRP
shRNA
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4628 ARTICLE
NATURE COMMUNICATIONS | 5:3628 | DOI: 10.1038/ncomms4628 | www.nature.com/naturecommunications 3
& 2014 Macmillan Publishers Limited. All rights reserved.
does not modify the single-channel conductance of CaV2.2
(Fig. 3a–c). Alternatively, a reduction of open probability of the
channels could also account for a lower whole-cell current
density. We therefore estimated CaV2.2 maximum open
probability by comparing the maximal ON-gating charge
displaced (Qmax) with the whole-cell conductance (Gmax) for
each cell19 (Fig. 3d–h). We found that Qmax for CaV2.2 was
reduced by 38% when FMRP was co-expressed, suggesting there
are fewer channels in the plasma membrane; but neither the
gating charge kinetics (Fig. 3f) or voltage dependence (Fig. 3g),
nor the estimated channel maximum open probability (Fig. 3h)
were modiﬁed. Taken together, our results indicate that FMRP is
likely to act by reducing the number of available CaV2.2 channels
on the cell surface.
FMRP reduces cell surface CaV2.2 via proteasomal degrada-
tion. To test for FMRP regulation of CaV2.2 protein expression,
we compared CaV2.2 protein level in tsA-201 cells transfected
with or without FMRP (Fig. 4a). We found that FMRP does not
affect total CaV2.2 protein level, or expression of the auxiliary
subunits (Fig. 4b and Supplementary Fig. 2).
Therefore, we assessed plasma membrane expression of CaV2.2
using a cell surface-biotinylation assay, and observed that
biotinylated CaV2.2 was signiﬁcantly reduced in the presence of
FMRP, by 28.7% (Fig. 4c–g). CaV2.2 plasma membrane
expression was further investigated by immunocytochemistry
using an extracellular HA-tagged CaV2.2 channel construct
(Fig. 4e). We found that HA-CaV2.2 immunoreactivity at the
cell surface of non-permeabilized cells was reduced by 43.9%
when CaV2.2 was co-expressed with FMRP (Fig. 4g). The
reduction of CaV2.2 cell surface expression determined by both
methods is in agreement with the reduction of current density
that we observed (Fig. 2).
CaV channels are subject to degradation by the protea-
some20,21. To test whether FMRP inﬂuences the targeting of
cell surface-expressed CaV2.2 to the proteasome, we examined the
effect of the proteasome inhibitor MG132 on CaV2.2 protein
levels in the absence or presence of FMRP (Fig. 4d–f). We ﬁrst
conﬁrmed that MG132 treatment was effective in blocking the
degradation of CaV2.2 expressed in tsA-201 cells (total CaV2.2
level is increased by 56% in cells treated with MG132 compared
with control, Supplementary Fig. 3). Then, using both the
biotinylation assay and immunocytochemistry, we found
that MG132 treatment abolished the reduction of CaV2.2
surface expression induced by FMRP (Fig. 4h). Together, our
results indicate that FMRP modulates CaV2.2 expression at the
plasma membrane by targeting the channels for proteasomal
degradation.
Cav2.2
Cav2.2
mVa b
c d
e f
g h
–50 0 50
***100
1.0
0.5
0.0
1.0
0.5
0.0
–100
–50
–150
–50
Conditioning potential (mV)
0
500
mV
I /
Im
a
x
N
or
m
al
iz
ed
 ta
il c
ur
re
nt
–50 0 10050
Potential (mV)
IBa(pA/pF)
Cav2.2
+70 mV
+90 mV
–100 mV –50 mV
–100 mV –50 mV 1 nA
40 ms
1 nA
5 ms
+ FMRP
+ FMRP
Cav2.2
+ FMRP
Cav2.2
+ FMRP
Cav2.2
***ICa(pA/pF)
+ FMRP
+ FMRP
Cav2.2
+10 mV
–100 mV 0.5 nA
20 ms
+ FMRP
Cav2.2
–100 mV
+10 mV
200 ms
+ FMRP
Figure 2 | FMRP reduces CaV2.2 current density. Recordings were made
from tsA-201 cells transfected with CaV2.2/CaVb1b/CaVa2d-1, with or
without GFP-FMRP. (a) CaV2.2 current traces elicited by 100ms step
depolarizations between  50 and þ 70mV from a HP of  100mV, for
CaV2.2 (top) and CaV2.2þ FMRP (bottom). The charge carrier was 1mM
Ba2þ . (b) Current–voltage relationship obtained with CaV2.2 (ﬁlled squares,
n¼ 5) and CaV2.2þ FMRP (red open squares, n¼ 8). V50,act¼ 0.4±0.4
and 1.4±1.2mV, respectively, and Gmax¼ 1.7±0.1 and 0.4±0.1 nS/pF,
respectively. At þ 10mV, peak CaV2.2 IBa current density were
 76.5±12.6 pA/pF (n¼ 5) and  15.1±7.1 pA/pF (n¼8, P¼0.007) for
CaV2.2 and CaV2.2þ FMRP, respectively (means±s.e.m., ***Po0.001;
one-way ANOVA). (c) Current traces illustrating current activation for
CaV2.2 (top) and CaV2.2þ FMRP (bottom). Peak tail currents were recorded
after repolarization to  50mV after a 20ms test pulse between  50 and
þ90mV from a HP of  100mV. (d) Voltage dependence of activation for
CaV2.2 (ﬁlled squares) and CaV2.2þ FMRP (red open squares).
V50¼ þ 13.8±1.8mV for CaV2.2 and þ 11.2±2.8mV for CaV2.2þ FMRP
(n¼ 6; means±s.e.m., P¼0.444; one-way ANOVA). (e) Current traces
illustrating steady-state inactivation for CaV2.2 (top) and CaV2.2þ FMRP
(bottom). Ba2þ currents were recorded after conditioning pulses of 10-s
duration, applied from a HP of  100mV in 10mV steps between  110 to
0mV, followed by a 50ms test pulse to þ 10mV. (f) Voltage dependence of
steady-state inactivation for CaV2.2 (ﬁlled squares) and CaV2.2þ FMRP
(red open squares). V50,inact¼  74.3±1.2mV for CaV2.2 (n¼ 5) and
66.3±1.8mV for CaV2.2þ FMRP (n¼ 6; means±s.e.m., P¼0.007;
one-way ANOVA). (g) Normalized current traces for CaV2.2 (black) and
CaV2.2þ FMRP (red) in response to 800ms depolarization step to þ 10mV
from a HP of  100mV. Mean time constants of inactivation (tinact)
obtained by ﬁtting the decaying phase of the current at þ 10mV with a
single exponential were 228±37ms (n¼ 7) and 198±17ms (n¼8,
means±s.e.m., P¼0.46; one-way ANOVA) for CaV2.2 and CaV2.2þ FMRP,
respectively. (h) Current–voltage relationship obtained in cells transfected
with CaV2.2 (ﬁlled squares, n¼ 7) and CaV2.2þ FMRP (open squares,
n¼ 11) using 1mM Ca2þ as a charge carrier and N-methyl-D-glucamine in
the pipette solution. V50,act¼  12.4±0.4mV and  9.7±0.4mV,
respectively, and Gmax¼ 2.2±0.1 and 1.1±0.1 nS/pF, respectively. At 0mV,
peak CaV2.2 current density were 96.6±8.9 pA/pF (n¼ 7) and
43.7±8.0pA/pF (n¼ 11, P¼0.0005) for CaV2.2 and CaV2.2þ FMRP,
respectively. Means±s.e.m., ***Po0.001; one-way ANOVA.
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FMRP interacts with CaV2.2 channels. To determine whether
FMRP interacts with CaV2.2, we ﬁrst used immunoprecipitation
on whole-cell lysate from tsA-201 cells expressing CaV2.2 and
HA-FMRP. We found that an HA Ab co-immunoprecipitates
CaV2.2 together with HA-FMRP (Fig. 5a). The interaction is
likely to be directly with CaV2.2 because HA-FMRP does not co-
immunoprecipitate the co-expressed auxiliary CaVb1b or
CaVa2d-1 subunits (Fig. 5a), also pointing to the possibility that it
might interact preferentially with channels that are not in func-
tional complexes with their auxiliary subunits. The interaction
between CaV2.2 and FMRP was conﬁrmed with an in situ
proximity ligation assay (PLA). Using GFP Ab to detect GFP-
CaV2.2 and FMRP Ab to detect HA-FMRP, we found PLA-
positive signals only in cells expressing GFP-CaV2.2 (Fig. 5b);
notably, the signal was present within the cytoplasm, as well as at
the plasma membrane.
To identify which domain of FMRP is involved in interaction
with CaV2.2, we performed pull-down experiments using
glutathione S-transferase (GST) fusion proteins with FMRP N-
terminal or C-terminal domains (Fig. 5c). We applied whole-cell
lysate from tsA-201 cells expressing CaV2.2/CaVb1b/CaVa2d-1 to
each puriﬁed GST-fusion protein, and found that only the
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Figure 3 | Effect of FMRP on biophysical properties of CaV2.2. (a,b) Noise analysis for CaV2.2 currents recorded in 10mM Ba
2þ from tsA-201 cells
transfected with CaV2.2 (a) or CaV2.2þ FMRP (b), plus a2d-1/b1b. Average currents in response to a 50ms step depolarization to  5mV from  100mV
(average of 80 depolarization steps). Inset, variance-current plot. The unitary current at  5mV, i, determined from the slope, is 0.69 pA for CaV2.2 and
0.70 pA for CaV2.2þ FMRP. (c) Plot of unitary current estimated from noise analysis plotted against test potential for CaV2.2 (ﬁlled circles) and
CaV2.2þ FMRP (red open circles). A minimum of three test potentials were recorded per cell (3–5 cells). The slope, determined by linear regression
corresponding to the single-channel conductance, was 16.4±1.1 pS and 17.4±1.2 pS for CaV2.2 and CaV2.2þ FMRP, respectively. (d,e) Traces showing
gating currents for CaV2.2 and CaV2.2þ FMRP measured at reversal potential (average of 10 depolarization steps). Inset, ON-gating current, taken from the
boxed areas. ON-gating current densities were 14.9±1.6 pA/pF (n¼ 23) and 10.5±1.2 pA/pF (n¼ 24) for CaV2.2 and CaV2.2þ FMRP, respectively
(means±s.e.m., P¼0.028; one-way ANOVA). (f) Peak ON-gating current properties for CaV2.2 (ﬁlled bars, n¼ 8) and CaV2.2þ FMRP (red open bars,
n¼ 11). Width (at 50% of the maximum gating current): 0.54±0.01ms for CaV2.2 and 0.53±0.07ms for CaV2.2þ FMRP (P¼0.9); TTP (time-to-peak):
0.25±0.06ms for CaV2.2 and 0.29±0.12ms for CaV2.2þ FMRP (P¼0.3); and td (decay time constant): 0.58±0.05ms for CaV2.2 and 0.57±0.13ms
for CaV2.2þ FMRP (P¼0.6). Means±s.e.m., one-way ANOVA. (g) Voltage dependence of ON-gating current activation for CaV2.2 (ﬁlled squares)
and CaV2.2þ FMRP (red open squares). CaV2.2 currents were elicited by 20ms step depolarizations between  50 and þ 60mV from  100mV. Mean
data are ﬁtted with a Boltzmann function, V50¼ þ 29.9±1.2mV for CaV2.2 and þ 28.5±0.9mV for CaV2.2þ FMRP (n¼ 6; P¼0.94). Means±s.e.m.,
one-way ANOVA. (h) Relationship between maximum whole-cell conductance (Gmax) and maximum gating charge (Qmax) for CaV2.2 (closed circles) and
CaV2.2þ FMRP (red open circles). At reversal potential, Qmax was 203.4±27.4fC (n¼ 20) and 125.0±20.6fC (n¼ 16, P¼0.035) for CaV2.2 and
CaV2.2þ FMRP, respectively (means±s.e.m., one-way ANOVA). Data were ﬁtted by linear regression (CaV2.2, black; CaV2.2þ FMRP, red). The slopes
(Gmax/Qmax), proportional to maximal channel open probability were 0.069±0.018 nS/fC (n¼ 20 cells) and 0.076±0.019 nS/fC (n¼ 16 cells) for
CaV2.2 and CaV2.2þ FMRP, respectively.
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Supplementary Fig. 8. (b) Expression of total CaV2.2 in tsA-201 cells expressing CaV2.2 (black squares, 100.0±10.6%, n¼ 7) and CaV2.2þ FMRP (open
red squares, 86.5±5.3%, n¼ 7, P¼0.27). The intensity of the signal was expressed relative to that of the GFP band in each experiment. Black bars
represent the means±s.e.m.; one-way ANOVA. (c) Cell surface-biotinylation assay of tsA-201 cells expressing CaV2.2 (left) or CaV2.2þ FMRP (right),
plus CaVb1b/CaVa2d-1. Biotinylated samples (Surface, top) and whole-cell lysates (Total, bottom) were immunoblotted with Abs against CaV2.2
and Akt (as a control for lack of biotinylation of cytoplasmic proteins). (d) Cell surface-biotinylation assay of tsA-201 cells, expressing CaV2.2 or
CaV2.2þ FMRP, plus CaVb1b and CaVa2d-1, treated with the proteasome inhibitor MG132 (5 mM) for 15 h. Biotinylated samples (Surface, top) and whole-
cell lysates (Total, bottom) were immunoblotted with CaV2.2 and Akt Abs. (e) Confocal images of non-permeabilized tsA-201 cells expressing
HA-CaV2.2þCaVb1bþCaVa2d-1 without (left) or with FMRP (right), immunostained for HA (white). Scale bar, 20mm applies to both images. (f) Confocal
images of non-permeabilized tsA-201 cells expressing HA-CaV2.2þCaVb1bþCaVa2d-1 without (left) or with FMRP (right), treated with MG132, as in (d),
immunostained for HA (white). Scale bar, 20mm applies to both images. (g) Surface expression of CaV2.2 in tsA-201 cells expressing HA-CaV2.2 (ﬁlled
bars) or HA-CaV2.2þ FMRP (open bars), plus CaVb1b/CaVa2d-1. Left: The surface-biotinylated CaV2.2 band was corrected for the intensity of the total
CaV2.2 in each experiment (CaV2.2: 100.0±3.2%, n¼ 16; CaV2.2þ FMRP: 71.3±7.8%, n¼ 17, P¼0.001). Right: HA surface immunoreactivity was
normalized to the CaV2.2 condition following correction for the background noise (CaV2.2: 100.0±3.8%, n¼ 200 cells; CaV2.2þ FMRP: 56.1±3.3%,
n¼ 198 cells, Po0.00001). Means±s.e.m., **Po0.01; ***Po0.001; one-way ANOVA. (h) Surface expression of CaV2.2 in tsA-201 cells expressing CaV2.2
(ﬁlled bars) or CaV2.2þ FMRP (red open bars), following treatment with MG132. Left: Surface-biotinylated CaV2.2 (CaV2.2: 100.0±4.2%, n¼ 7;
CaV2.2þ FMRP: 92.9±5.6%, n¼ 7, P¼0.33). Right: HA immunoreactivity (CaV2.2: 100.0±4.3%, n¼ 174 cells; CaV2.2þ FMRP: 102.4±5.6%, n¼ 142
cells, P¼0.72). Means±s.e.m.; one-way ANOVA.
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cells, but not in control (Ab omitted). CaVb1b and CaVa2d-1 were also transfected but neither were co-immunoprecipitated with HA-FMRP. Immunoblots
were performed using CaV2.2, CaVa2d-1, CaVb1b and HA Ab. Representative of three experiments. (b) Confocal images of in situ PLA showing interaction
between transfected GFP-tagged CaV2.2 and HA-FMRP in tsA-201 cells. CaVb1b and CaVa2d-1 were also transfected. PLA was performed using mouse
FMRPAb (7G1-1) and either rabbit IgG (top row) or rabbit anti-GFP Ab (bottom row). PLA signals (white, right panel) are detected only in cells positive for
GFP-CaV2.2 (green, left panel) when both GFP and FMRP Abs were used. 4
0,6-diamidino-2-phenylindole (blue) labels cell nuclei. Scale bar, 10mm.
Representative of three experiments. (c) Schematic depiction of FMRP and GST-fusion fragments used for pull-down assay. Nter, N-terminus; Cter,
C-terminus; KH1 and KH2, K-homology domains 1 and 2; RGG, arginine-glycine-glycine box; FNT, GST-FMRP N-terminus; FCT, GST-FMRP C-terminus; aa,
amino acid. (d) Western blots of pull-down assays show FCT, but not GST alone or FNT, binds CaV2.2 expressed in tsA-201 cells plus CaVb1b/CaVa2d-1.
Input represents 5% of protein input included in the assay. Western blots (lower panel) show amount of GST-tagged protein used in the assay.
Representative of three experiments. (e) Western blots of pull-down assays show neither CaVa2d-1 nor CaVb1b expressed in tsA-201 cells (together with
CaV2.2) were pulled down with FCT. Input represents 5% of protein input included in the assay. Immunoblots were performed using CaVa2d-1 and CaVb1b
Ab. Representative of three experiments. (f) CaV2.2 and mutant CaV2.2 (W391A) expressed in tsA-201 cells (with CaVa2d-1/CaVb1b) were both
pulled down with FCT. Input represents 5% of protein input included in the assay. Representative of three experiments. (g,h) Western blots of pull-down
assays show phosphorylation state of FMRP serine 499 does not modify interaction with CaV2.2. (g) S499A, dephosphomimetic-FCT; (h) S499D,
phosphomimetic-FCT. Input represents 5% of protein input included in the assay. Representative of three experiments. Full-size blots can be found
in Supplementary Fig. 8.
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C-terminal domain of FMRP pulled down CaV2.2 (Fig. 5d). We
further showed that the C-terminal domain of FMRP is necessary
for its functional effect because FMRP with a deletion of its
C-terminal domain is unable to reduce CaV2.2 current density
(Supplementary Fig. 4). The interaction is speciﬁc for CaV2.2
because neither CaVb1b nor CaVa2d-1 was pulled down (Fig. 5e).
We also found that CaV2.2 containing a mutation (W391A) that
prevents binding of CaVb subunits to its I-II linker22 retains its
ability to interact with the FMRP C-terminus, further suggesting
that the interaction between FMRP and CaV2.2 is independent of
CaVb (Fig. 5f). Finally, the interaction of FMRP with CaV
channels appears to be speciﬁc for the CaV2 family since CaV2.1
but not CaV1.2 channels binds to the FMRP C-terminus
(Supplementary Fig. 5).
FMRP is phosphorylated primarily on the conserved S499 in its
C-terminal domain1. To test whether this key serine is involved in
the interaction with CaV2.2, we mutated S499 into either an
alanine (S499A, dephosphomimetic)23 or an aspartic acid
(S499D, phosphomimetic)5. We performed GST pull-down
experiments and found that neither mutation prevented the
binding of FMRP C-terminus to CaV2.2 (Fig. 5g,h).
FMRP interacts with CaV2.2 in vivo. We then examined whether
the interaction between FMRP and CaV2.2 occurs in neurons. We
ﬁrst showed that FMRP interacts with CaV2.2 endogenously, by
immunoprecipitation of either CaV2.2 or FMRP from brain
synaptosomes. We found that a CaV2.2 Ab co-immunoprecipi-
tates FMRP (Fig. 6a), and reciprocally we showed that an FMRP
Ab co-immunoprecipitates CaV2.2 (Fig. 6b). We also conﬁrmed
that the FMRP C-terminal domain interacts with synaptosomal
CaV2.2 (Fig. 6c). FMRP is expressed in DRG neurons throughout
the soma and processes24 (Supplementary Fig. 6). To determine
whether the interaction between FMRP and CaV2.2 occurs in
neurons, we transiently transfected DRG neurons with
GFP-CaV2.2 and performed in situ PLA using anti-GFP Ab and
anti-FMRP Ab. We found PLA-positive signals in somata and
processes of DRG neurons expressing GFP-CaV2.2, showing that
endogenous FMRP also forms protein complexes with CaV2.2
both in DRG neuron cell bodies and in their neurites (Fig. 6d–f).
FMRP interacts with CaV2.2 synaptic targeting domains. We
then focused on identifying the domains of CaV2.2 involved in
the interaction with FMRP. We generated a series of GFP-tagged
constructs corresponding to intracellular regions of CaV2.2
(Fig. 7a). We expressed each construct individually in tsA-201
cells and applied the whole-cell lysate to immobilized GST-FMRP
C-terminus (Fig. 7b–g). We found that the II–III linker (Fig. 7d)
and the C-terminus of CaV2.2 (Fig. 7f) were both pulled down by
FMRP C-terminus, but the other intracellular regions were not
(Fig. 7b,c,e). Interestingly, these two intracellular regions of
CaV2.2 are both involved in the interaction with presynaptic
proteins25. The II–III linker contains a synaptic protein
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e) or rabbit anti-GFP Ab (d, bottom row; f). PLA signals (white) are detected in soma (d) and process (e,f) of DRG positive for GFP-CaV2.2 (green) when
both GFP and FMRP Abs were used. Scale bar, 20mm. Representative of three experiments.
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interaction (synprint)25 site and we found that this synprint
motif on its own retains the ability to bind to FMRP
C-terminus (Fig. 7g).
FMRP controls synaptic release via N-type calcium channels.
CaV2 channels have a major presynaptic role in regulation of
transmitter release12,13, and CaV2.2 is particularly important in
the peripheral nervous system. In order to determine the
physiological impact of the interaction between FMRP and
CaV2.2 channels, we assessed the effect of loss of FMRP on
synaptic vesicle release. We used the vGlut1-pHluorin (vGpH)
optical reporter to measure synaptic vesicle recycling in DRG
neurons co-cultured with DH neurons26. E18 DRG neurons were
co-transfected with mCherry, vGpH and either Ctrl shRNA or
FMRP shRNA and then plated with untransfected DH neurons.
DRG neurons were imaged after 9–11 days in culture. vGpH
colocalized in varicosities with presynaptic marker synapsin and
was in apposition to postsynaptic marker PSD-95 (Fig. 8a). We
monitored the increase in ﬂuorescence of vGpH in response to 40
action potentials at 10Hz (Fig. 8b). Signals from each bouton
were normalized to the ﬂuorescence value obtained by rapid
alkalinization of the entire labelled vesicle pool using NH4Cl
(Fig. 8b). We found that responses to 40 action potentials at
10Hz were increased by 37% in synapses from DRG neurons
in which FMRP was knocked down compared with control
(Fig. 8c–e). During stimulation, the change of vGpH signal
reﬂects the difference between exocytosis and ongoing vesicle
endocytosis and reacidiﬁcation27. After stimulation, the signal
decays due to endocytosis of vGpH and vesicle reacidiﬁcation. We
then examined synaptic vesicle recycling by stimulating neurons
at 40Hz for 30 s and monitoring the time course of ﬂuorescence
decay. We found that the rate of decay was not different in
boutons of DRG neurons lacking FMRP compared with controls
(Fig. 8f). We can then conclude that the increase of vesicle release
during stimulation of synaptic terminals of which FMRP was
knocked down is due to an increase in exocytosis. Interestingly,
we recorded a similar increase in vesicle release in synapses from
the hippocampal neurons expressing FMRP shRNA (37.5%
increase compared with Ctrl shRNA, Supplementary Fig. 7),
suggesting that FMRP is also involved in vesicular release in
central nervous system synapses.
Using speciﬁc blockers for CaV2.2 and CaV2.1 channels
(o-conotoxin GVIA and o-agatoxin IVA, respectively), we
showed that in control synapses 55.3% of the exocytosis was
inhibited by o-conotoxin GVIA and that 82.7% was blocked by
o-conotoxin GVIAþo-agatoxin IVA co-application (Fig. 8c–e).
Remarkably, at synapses of DRG neurons in which FMRP was
knocked down, o-conotoxin GVIA reduced exocytosis to a level
comparable with the control (inhibition of 58.4%, Fig. 8e) and
therefore abolished the increase induced by the lack of FMRP.
Finally, o-conotoxin GVIA together with o-agatoxin IVA
reduced exocytosis by 82% in DRG neurons in which FMRP
was knocked down (Fig. 8e). Together, these data demonstrate
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that FMRP regulates vesicle exocytosis via CaV2.2 channels in
DRG neurons.
Discussion
FXS, the most common heritable form of mental retardation, is
characterized by synaptic dysfunction and is caused by the loss of
FMRP1,2. Regulation of CaV expression at presynaptic terminals
is a critical factor in the control of synaptic transmission. In this
study, we show that FMRP exerts a tonic inhibition of somatic
CaV current density and CaV2.2 surface expression at presynaptic
terminals of DRG neurons. We also show that FMRP reduces
CaV2.2-generated currents by decreasing the expression of the
channels at the plasma membrane, and we provide evidence that
this mechanism depends on proteasomal degradation. We
demonstrate that the interaction between FMRP and CaV2.2 is
direct, since we ﬁnd that the C-terminal domain of FMRP binds
to the CaV2.2 II–III linker and its C-terminal domain. Finally, we
show that FMRP controls synaptic vesicle exocytosis via CaV2.2
channels. Our study demonstrates a hitherto unknown effect of
FMRP on CaV2.2 expression and indicates a major presynaptic
function for FMRP.
In this study, we show that FMRP affects CaV2.2 cell surface
expression at the presynaptic element of DRG neurons and
modulates synaptic transmission by this means. Consistent with
this hypothesis, studies in animal models of FXS show an increase
in transmitter release at the Drosophila neuromuscular junction7,8
and an increase of synaptic vesicle recycling in mouse
hippocampal neurons10. However, the lack of FMRP has also
been associated with decrease of synaptic transmission7,28,29, and
FMRP appears to regulate multiple synaptic parameters
depending on the developmental stage and the area of the
nervous system.
CaV2.1 and CaV2.2 channels are the two major classes of CaV
in presynaptic terminals, whereas CaV1.2 channels are located
mainly in postsynaptic elements14. We show that FMRP interacts
with CaV2.1 and CaV2.2, but not with CaV1.2 channels,
suggesting that the interaction is speciﬁc for presynaptic
calcium channels (Supplementary Fig. 5). We also show that
FMRP interacts with the II–III linker synprint site and C-terminal
region of CaV2.2. Several presynaptic proteins have been found to
interact with CaV2.2 channels, including SNARE proteins
syntaxin 1A and SNAP-25 (refs 25,30) and active-zone proteins
including Rab-interacting molecule (RIM)31. The interaction
between SNARE proteins and CaV2.2 synprint site has been
found to modulate the targeting of the CaV2.2 channel to the
nerve terminals of both peripheral sympathetic ganglion
neurons32 and central hippocampal neurons33 and also to
inhibit calcium currents34. Moreover, CaV2.2 channels, via a
postsynaptic density-95/discs large/zona occludens-1 (PDZ)
domain binding motif and a proline-rich region located in the
CaV2.2 C-terminal domain, can directly interact with Mint,
CASK, RIM1 and RIM-BP2 to target the channels to presynaptic
active zones35,36. G protein-coupled receptor have also been
shown to associate with Cav2.2 via the II–III linker and the
C-terminal domain37 and this can alter the expression of the
Cav2.2 channels at the plasma membrane38,39. These interactions
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Figure 8 | FMRP knockdown enhances synaptic vesicle exocytosis in
presynaptic terminals of DRG neurons via CaV2.2 channels.
(a) Presynaptic terminals of DRG neurons expressing vGpH (vGpH).
Images show vGpH ﬂuorescence (green) colocalized with endogenous
synapsin 1 and 2 (left panel, red) and apposed to endogenous PSD-95 (right
panel, red). Synapses are indicated by the white arrows. Scale bars, 5mm.
(b) Fluorescence changes (DF) of vGpH in presynaptic terminals
of DRG neurons transfected with Ctrl shRNA (top panels) or FMRP shRNA
(bottom panels) in response to electrical stimulation. Left panels: at rest;
middle panels: after 40 action potentials (AP) at 10Hz; right panels: after a
brief application of NH4Cl. Responsive terminals are indicated by the
black arrows. Pseudocolor scale is shown to the right (min, max:minimum
and maximum ﬂuorescence intensity). Scale bar, 10 mm. (c,d) vGpH
response to 40 AP at 10Hz from presynaptic terminals of DRG neurons
transfected with Ctrl shRNA (c) or FMRP shRNA (d) before and after
treatment with toxins (10min with o-conotoxin GVIA (1mM) and o-
agatoxin IVA (300nM)). Fluorescence intensities were normalized to the
peak of a brief application of NH4Cl. (e) Normalized vGpH responses to 40
AP at 10Hz from presynaptic terminals of DRG neurons transfected with
Ctrl shRNA (black-ﬁlled bar, 100±10.6%, n¼ 38) or FMRP shRNA (red
open bar, 137.0±12.6%, n¼ 25, P¼0.027). o-conotoxin GVIA (ConoTx,
1mM) reduces Ctrl shRNA and FMRP shRNA responses to a similar level
(44.7±4.9%, n¼ 15 and 41.6±3.3%, n¼ 24, respectively). o-conotoxin
GVIA (1mM) and o-agatoxin IVA (AgaTx, 300 nM) application reduces
further the responses: Ctrl shRNA¼ 17.3±3.2%, n¼ 38, and FMRP
shRNA¼ 18.1±5.0%, n¼ 27. A dot plot graph for the data is presented
in Supplementary Fig. 9. Means±s.e.m., *Po0.05; one-way ANOVA.
(f) Average vGpH response to a 40Hz stimulation for 30 s from
presynaptic terminals of DRG neurons transfected with Ctrl shRNA (black-
ﬁlled squares) or FMRP shRNA (open red squares). The decay of the
signal after stimulation is well ﬁtted by a monoexponential: t¼ 20.3±2.3 s
for Ctrl shRNA (n¼ 111) and t¼ 20.9±0.9 s for FMRP shRNA (n¼ 77).
Means±s.e.m.
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provide an effective association between Ca2þ entry and the
vesicle release sites that ensures the rapid triggering of
neurotransmitter release when an action potential invades the
nerve terminal. Precisely how the interaction with FMRP affects
CaV2.2 synaptic localization is still unclear and further
investigation is required to elucidate this process.
Several mechanisms can control CaV expression at the plasma
membrane; among them interactions with the auxiliary CaVa2d-1
subunits markedly affect their functional expression11. We show
that FMRP does not affect CaVa2d-1 expression and does not
interact with CaVa2d-1, making it unlikely that FMRP affects
CaV2.2 surface expression via a CaVa2d subunit-dependent
mechanism, despite the role of CaVa2d proteins in presynaptic
calcium channel targeting26. Trafﬁcking and surface expression of
CaV also depends on the interaction with auxiliary CaVb
subunits11. Recent studies have shown that the interaction of
CaV1 and CaV2 channels with CaVb subunits protects these
channels against proteasomal degradation20,21. Interestingly, we
ﬁnd here that the effect of FMRP on CaV2.2 expression is
antagonized by a proteasome inhibitor, and we found that
the interaction between FMRP and Cav2.2 does not
co-immunoprecipitate CaVb subunits, suggesting that it occurs
with channels that have lost, or subsequently lose, the protective
interaction with CaVb subunits11. Nevertheless, further work is
needed to unravel the molecular mechanism by which FMRP
targets CaV2.2 for degradation. For example, does FMRP also
interact with an element of the proteasome and thus target
CaV2.2 to this pathway, in which case FMRP would play the role
of a molecular adaptor?
Our ﬁndings reveal that FMRP interacts directly with the
CaV2.2 channel protein, both in vitro and in cultured DRG
neurons. A recent study has reported that FMRP can directly
interact and modulate the gating of the sodium-activated
potassium channel Slack-B15. Whereas in this latter report, the
FMRP N-terminal domain is shown to be involved in the
interaction with Slack-B, we ﬁnd here that the FMRP C-terminal
domain interacts with CaV2.2. The FMRP N-terminal domain is a
well-described platform for protein–protein interactions40 but
only two reports have so far described protein–protein
interactions with FMRP C-terminal domain: the motor protein
kinesin light chain involved in RNA granule and axonal
transport3 and the scaffolding protein Ran-binding protein in
the microtubule-organizing centre (RanBPM), which is associated
with synapse formation in neurons41,42. The FMRP C-terminal
domain is a non-conserved region in the related proteins FXR1P
and FXR2P1. Altogether, these data reinforce the hypothesis that
the FMRP C-terminal domain contributes to determining the
speciﬁcity of FMRP function41.
More recently, FMRP has been shown to interact with large-
conductance calcium-activated potassium (BK) channel via their
auxiliary b4 subunit and to regulate neurotransmitter release at
hippocampal CA3-CA1 synapses by modulating action potential
duration in the soma of CA3 neurons16. This latter study also
described that the intracellular perfusion of FMRP Ab induces an
increase of calcium transient in presynaptic boutons of CA3
neurons, although the mechanism behind this increase of calcium
transient was not examined. BK channels are modulators of
action potential duration in the soma of CA3 neurons, but their
involvement in presynaptic vesicle exocytosis is still a matter of
debate43. Further investigation is needed to identify the
mechanism by which FMRP modulates the calcium transient in
the CA3-CA1 hippocampal synapses but our results support the
view of an involvement of CaV2 channels.
Taken together, our data demonstrate a direct and tonic role
for FMRP in regulating presynaptic N-type calcium channel
expression and function in DRG neurons. Presynaptic CaV2.2
channels are critical for neurotransmission, both in central
neurons and in the autonomic and sensory nervous system, where
they are involved in nociception and short-term synaptic
plasticity14,44. Therefore, dysregulation of CaV2.2 expression
could account for aspects of the cognitive impairment and
altered pain sensitivity observed both in patients and in a mouse
model of FXS24,45,46. Consistent with this hypothesis, a clinical
trial using a g-aminobutyric acid type B (GABAB) agonist
(R-baclofen), an inhibitory modulator of N-type calcium
channels47, found some improvement of social function and
behaviour in FXS patients48. Our study opens the possibility
that small molecule inhibitors of CaV2.2, currently being
developed for a number of chronic pain conditions49, could be
of beneﬁt in FXS.
Methods
cDNA constructs. The following cDNAs were used: CaV2.2 (D14157), CaV2.1
(M64373), CaV1.2 (M67515), CaVb1b (X61394; from Dr T. P. Snutch,), CaVa2d-1
(Genbank accession number AF_286488), mut-3b GFP(M62653, except S72A and
S65G, Dr T. E. Hughes), all subcloned in pMT2 for expression in tsA-201 cells and
subcloned in pcDNA3.0 or pRK5 vectors for expression in neurons. peGFP-FMRP
(NBCI nucleotide accession code NM_008031.2) was a gift from Dr G. J. Bassell;
Vamp-mCherry and vGlut-pHluorin was a gift from Dr T.A. Ryan. The HA-tagged
CaV2.2 construct was generated with an HA tag in an extracellular linker, similar to
that previously described20. Truncated and GFP-tagged CaV2.2 constructs
(Nter-GFP, I-II-GFP, GFP-II–III, GFP-synprint, GFP-III–IV and GFP-Cter) and
HA-FMRP were generated using standard molecular biological techniques and
conﬁrmed by DNA sequencing. All constructs were cloned into the pcDNA3.0
vector for expression in mammalian cells. shRNA plasmids were generated as
previously described50 using the following mRNA target sequence for FMRP:
50-GTGATGAAGTTGAGGTTTA-30 (ref. 51).
Cell culture and transfection. tsA-201 cells (96121229, ECACC) were cultured in
Dulbecco’s modiﬁed Eagle’s medium with 10% fetal bovine serum (FBS), penicillin
and streptomycin, and 2% GlutaMAX (Invitrogen). tsA-201 cells were transfected
using FuGene6 reagent (Roche and Promega), following the manufacturer’s
instructions. P10 DRG neurons were prepared from male Sprague Dawley rats and
transfected using Amaxa Nucleofector (Lonza) according to the manufacturer’s
protocol. E18 and P2 rat DRG/DH neuron co-cultures were prepared from isolated
DRGs and spines. Neurons were dissociated by trypsinization (0.25%) followed by
trituration. Neurons were plated on glass coverslips coated with poly-L-lysine
and laminin and cultured in Neurobasal medium containing B27 supplement,
penicillin and streptomycin, NGF (100 ngml 1), and 2% GlutaMAX (Invitrogen).
One-half of the growth medium was replaced every 3 days. DRG neurons were
transfected before plating using Amaxa Nucleofactor (Lonza) according to the
manufacturer’s instructions or microinjected (Eppendorf microinjection system)
after 7 days in culture.
Western blot analysis. At 48 h after transfection, cells were rinsed twice with
phosphate-buffered saline (PBS) and then harvested in PBS containing protease
inhibitors (Complete tablet from Roche). The cells were lysed in PBS, 1% Igepal and
protease inhibitors for 30min on ice. The detergent lysates were then clariﬁed by
centrifugation (14,000 g, 30min, 4 C). Proteins were separated by SDS–PAGE on
3–8% Tris-acetate or 4–12% Bis-Tris gels and then transferred to polyvinylidene
ﬂuoride membranes. After blocking in Tris-buffered saline buffer (10mM Tris, pH
7.4, 500mM NaCl. 0.5% Igepal, 10% goat serum and 3% BSA), the membranes were
incubated with primary antibody overnight. The protein–Ab complexes were then
labelled with a horseradish peroxidase-conjugated secondary Ab (1:3,000 Sigma-
Aldrich) for 1 h at room temperature and detected using the enhanced ECL Plus
reagent (GE Healthcare) visualized with a Typhoon 9410 scanner (GE Healthcare).
Quantiﬁcation of immunoblot bands was performed with ImageQuant software
(GE Healthcare). The following Abs were used: rabbit anti-CaV2.2 (1:500)52, rabbit
anti-CaVb1b (1:500) and mouse anti-CaVa2d-1 (1:3,000, D219, Sigma).
Synaptosomal fraction preparation. Synaptosomal fractions were prepared by
differential centrifugation53. Whole rat brains were homogenized in: 0.32M
sucrose, 3mM HEPES-Na, pH 7.4 containing protease inhibitors. The homogenate
was centrifuged at 1,000 g for 10min to produce a pellet (P1) and a supernatant
(S1). The pellet P1 was resuspended in homogenization buffer and centrifuged at
1,000g for 10min to produce a pellet (P10) and a supernatant (S10). S1 and S10 were
combined and centrifuged at 12,000 g for 15min to produce a pellet P2 and a
supernatant S2. P2 was resuspended in homogenization buffer and centrifuged
15min at 13,000 g to produce the crude synaptosomal fraction P20 . P20 was
resuspended in 1% Igepal PBS, incubated for 30min on ice and clariﬁed by
centrifugation 30min at 12,000 g.
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Immunoprecipitation. Clariﬁed cell lysates or synaptosomal fractions were cleared
with 50 mg of protein A sepharose (GE Healthcare) for 1 h at 4 C. Supernatants
were incubated with 2 mgml 1 of speciﬁc Ab overnight at 4 C with constant
agitation. A further 20mg of protein A sepharose was added and incubated for 1 h
at 4 C. Beads were washed three times with PBS containing 0.1% Igepal and
incubated for 15min at 55 C with 100mM dithiothreitol and 2X Laemmli sample
buffer. Eluted proteins were then resolved by SDS–PAGE. The following Abs were
used: rat anti-HA (Roche), MAB 7G1-1 anti-FMRP (Developmental Studies
Hybridoma Bank, University of Iowa), MAB2160 anti-FMRP (Millipore) and
rabbit anti-CaV2.2.
Cell surface biotinylation. At 18 h after transfection, cells were rinsed twice with
PBS and then incubated with PBS containing 1mgml 1 Sulfo-NHS-SS-Biotin
(Perbio) for 30min at room temperature and then rinsed once with PBS and twice
with PBS containing 200mM glycine. Cells were then harvested and lysed in PBS,
1% Igepal and protease inhibitors for 30min on ice. The detergent lysates were
then clariﬁed by centrifugation (14,000 g, 30min, 4 C). Biotinylated proteins
were precipitated by adding 100 ml of streptavidin-agarose beads (Perbio) and
incubated overnight at 4 C. The streptavidin-agarose beads were washed three
times and incubated for 1 h at 37 C with 100mM dithiothreitol and 2x Laemmli
sample buffer. Eluted proteins were then resolved by SDS–PAGE. The following
Abs were used: rabbit anti-CaV2.2 (1:500)52 and rabbit polyclonal anti-Akt (9272,
1:1,000, Cell Signalling Technology).
GST pull-down assay. For pull-down assays, GST was subcloned into pYES2.1/
V5-His TOPO TA (Invitrogen) by inserting PCR product using pGEX-2T as a
template (GE Healthcare). GST-tagged constructs were generated by inserting PCR
products of the mouse FMRP N-terminal (nucleotides 266–1003) and C-terminal
(nucleotides 1514–2104) into EcoRI site of a pYES2.1/V5-His-GST. Yeasts
(Saccharomyces cerevisiae) were transformed with individual expression vectors
encoding the GST-fusion proteins and produced by standard methods. The yeast
was lysed by vigorous shaking in PBS containing protease inhibitors (Complete
tablet, Roche) and glass beads (Sigma) at 4 C for 20min. The lysates were then
clariﬁed by centrifugation (14,000 g, 5min, 4 C). GST-fusion proteins were
immobilized on glutathione sepharose 4B beads (GE Healthcare) and incubated at
4 C with lysate from tsA-201 cells transfected with full-length CaV2.2 or GFP-
tagged CaV2.2 constructs or synaptosomal fraction preparations. Beads were
washed four times with ice-cold 1% Triton-PBS containing protease inhibitors
(Complete tablet, Roche) and incubated for 15min at 55 C with 100mM
dithiothreitol and 2X Laemmli sample buffer. Eluted proteins were then resolved
by SDS–PAGE. The following Abs were used: rabbit polyclonal anti-CaV2.2
(ref. 52) (1:500), mouse monoclonal anti-GST (sc-138, 1:3,000, Santa Cruz
Biotechnology) and mouse monoclonal anti-GFP (632380, 1:3,000, Clontech).
Immunocytochemistry. Cells were ﬁxed with 4% paraformaldehyde/sucrose in
PBS for 5min and then permeabilized with 0.1% Triton X-100 in PBS for 10min at
room temperature. Cells were blocked with 10% FBS in PBS for at least 30min
at room temperature, and incubated with the primary Ab overnight with 3% FBS in
PBS. Primary antibodies used were as follows: rabbit anti-bIII-tubulin (T2200,
1:1,000, Sigma), rabbit anti-synapsin 1, 2 (106002, 1:200, Synaptic systems),
mouse anti-PSD-95 (ab2723, 1:200, Abcam). Samples were then washed and
incubated with secondary conjugated Ab (1:500; anti-rabbit AF594, A11072; anti-
rabbit AF633, A31573; anti-mouse AF594, A11005; anti-mouse AF633, A21050; all
from Invitrogen and anti-mouse FITC, F2012, from Sigma) for 1 h at room
temperature. After washing, samples were mounted in VectaShield (Vector
Laboratories). Cells were examined on LSM 510 Meta or LSM 780 confocal
microscopes (Zeiss).
In situ PLA. Cells were ﬁxed with 4% paraformaldehyde/sucrose in PBS for 5min,
incubated in 0.1M Tris HCl for 5min at room temperature and then permeabilized
with 0.1% Triton X-100 in PBS for 10min at room temperature. Cells were blocked
with 10% FBS/0.1% Tween 20 in 4 SSC for 30min at 37 C. Cells were incubated
overnight with the primary antibody pair (1:500) from different species, directed
against GFP (rabbit polyclonal anti-GFP, TP-401; Torrey Pines) and FMRP (mouse
monoclonal MAB 7G1-1, Developmental Studies Hybridoma Bank, University of
Iowa) and thereafter subjected to in situ PLA using Duolink Detection kit (Olink
Bioscience) according to the manufacturer’s instruction. Brieﬂy, after incubation
with primary antibodies, the cells were incubated with secondary antibodies con-
jugated with oligonucleotides (mouse PLA probe MINUS and rabbit PLA probe
PLUS, supplied in the PLA kit). Subsequently, connector oligonucleotides and
ligase were added; the connector oligonucleotides hybridize to the two PLA probes
and join to form a circular DNA strand when the PLA probes are in close
proximity. After ligation, a polymerase is added and rolling-circle ampliﬁcation is
initiated using one of the PLA probes as a primer. The ampliﬁcation product is
detected through hybridization of ﬂuorescently labelled oligonucleotides. Thus,
individual pairs of proteins generate a spot that can be visualized using ﬂuorescence
microscopy. The theoretical maximum distance between the 2 target proteins is
30–40 nm to be able to create a PLA signal.
Live cell imaging. Coverslips were mounted in a rapid-switching, laminar-ﬂow
perfusion and stimulation chamber (Warner Instruments) on the stage of an
epiﬂuorescence microscope (Axiovert 200M, Zeiss). Live cell images were acquired
with an Andor iXonþ (model DU-897U-CS0-BV) back-illuminated EMCCD
camera using OptoMorph software (Cairn Research, UK). White and 470 nm LEDs
served as light sources (Cairn Research, UK). Fluorescence excitation and collec-
tion was done through a 40 1.3 NA Fluar Zeiss objective using 450/50 nm
excitation and 510/50 nm emission and 480 nm dichroic ﬁlters (for pHluorin) and
a 572/35 nm excitation and low-pass 590 nm emission and 580 nm dichroic ﬁlters
(for mCherry). Action potentials were evoked by passing 1ms current pulses via
platinum electrodes. Cells were perfused (0.5mlmin 1) in a saline solution at
30 C containing (in mM) 119 NaCl, 2.5 KCl, 2 CaCl2, 2 MgCl2, 25 HEPES
(buffered to pH 7.4), 30 glucose, 10 mM 6-cyano-7-nitroquinoxaline-2,3-dione
(CNQX) and 50mM D,L-2-amino-5-phosphonovaleric acid (AP5, Sigma). o-con-
otoxin GVIA (1 mM) and o-agatoxin IVA (300 nM) were applied for 10min before
stimulation (Alomone Labs). NH4Cl applications were done with 50mM NH4Cl in
substitution of 50mM of NaCl (buffered to pH 7.4). Images were acquired at 2Hz
and analysed in ImageJ (http://www.rsb.info.nih.gov/ij) using a custom-written
plugin (http://www.rsb.info.nih.gov/ij/plugins/time-series.html).
Electrophysiology. Whole-cell patch-clamp recordings were performed on tsA-
201 cells or DRG neurons at room temperature (21–25 C). Single cells were
voltage clamped using an Axopatch 200B patch-clamp ampliﬁer (Axon instru-
ments). Patch pipettes were ﬁlled with a solution containing the following (in mM):
140 Cs-aspartate, 5 EGTA, 2 MgCl2, 0.1 CaCl2, 2 K2ATP and 10 HEPES, titrated to
pH 7.2 with CsOH. The external solution contained the following (in mM): 150
tetraethylammonium bromide, 3 KCl, 1 NaHCO3, 1 MgCl2, 10 HEPES, 4 glucose
and 1 BaCl2, pH adjusted to 7.4 with Tris base. Recordings from DRG neurons
were performed using 10mM BaCl2. Current density–voltage relationships were
ﬁtted with a modiﬁed Boltzmann equation as follows: (1) I¼Gmax (VVrev)/
(1þ exp( (VV50,act)/k)), where I is the current density (in pA/pF),
Gmax is the maximum conductance (in nS/pF), Vrev is the reversal potential, V50,act
is the midpoint voltage for current activation and k is the slope factor. Steady-state
inactivation and activation data were ﬁtted with a single Boltzmann equation of the
following form: (2) I/Imax¼ (A1A2)/[1þ exp((VV50,inact)/k/]þA2), where Imax
is the maximal current, and V50,inact is the half-maximal voltage for current inac-
tivation. For the steady-state inactivation, A1 and A2 represent the proportion of
inactivation and non-inactivating current, respectively. Inactivation kinetics of the
currents were estimated by ﬁtting the decaying part of the current traces with the
following equation: (3) I(t)¼CþA exp( (t t0)/tinact), where t0 is zero time,
C the fraction of non-inactivating current, A the relative amplitude of the
exponential, and tinact is the time constant.
Non-stationary ﬂuctuation analysis. Fluctuation analysis was carried out using
the method described by Sigworth54. Ensembles of currents were generated by a
series of identical voltage pulses delivered every 5 s. Currents were recorded using
10mM BaCl2 and ﬁltered at 2 kHz. The variance was calculated between successive
sweeps and then averaged over all the pairs. Background variance at the holding
potential was subtracted from the variance during the test pulse. Single-channel
current was estimated by plotting the variance as a function of the mean current
and ﬁtting the data by (4) variance¼ i I I2/N, where i is the unitary current, I is
the mean current and N is the number of functional channels55.
Gating currents. ON-gating currents were measured during test pulses to positive
potentials at which no ionic inward or outward currents were observed. Currents
were ﬁltered at 10 kHz. Patch pipettes were ﬁlled with a solution containing the
following (in mM): 150 N-methyl-D-glucamine (NMDG), 10 EGTA, 1 MgCl2, 10
HEPES and 4 Mg-ATP (adjusted to pH 7.3 with methanesulfonic acid). The
external solution contained the following (in mM): 135 choline chloride, 4 MgCl2,
10 Hepes and 1 CaCl2; pH adjusted to 7.2 with CsOH.
G/Q analysis. G/Q analyses were performed as previously described19. Gmax was
determined for each cell as the slope of the peak current–voltage relationship
(between þ 20mV and þ 60mV). Gmax is related to single-channel open
probability at maximal depolarization by the following equation: (5)
Gmax¼ POmaxng, where POmax is the single-channel open probability at maximal
depolarization, n is the number of channels and g is the single-channel
conductance. Qmax can be determined according to the following equation: (6)
Qmax¼ nqmax, where qmax is the maximum gating charge moved per single channel.
Plotting Gmax as a function of Qmax deﬁnes a linear relationship with a slope (7)
Gmax/Qmax¼ POmax(g/qmax). Assuming that the single-channel conductance is not
modiﬁed (Fig. 3c) and that the number of elementary charges moved are the same
(voltage dependence of activation of their gating currents are indistinguishable,
Fig. 3g) then the slope Gmax/Qmax is proportional to POmax.
Statistical analysis. Statistical analysis was conducted by one-way analysis of
variance followed by Tukey’s multiple comparison tests. Statistical signiﬁcance
was set at Po0.05, and all error bars represent s.e.m.
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